# EDGAR Filing Document

**Accession Number:** 0001498382
**File Stem:** 0000000000-25-009257
**Filing Date:** 2025-8
**Character Count:** 3582
**Document Hash:** fd260d3f6e5d7c0ebe449e19d6ff4dde
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-25-009257.hdr.sgml**: 20260218

**ACCESSION NUMBER**: 0000000000-25-009257

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250828

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** TuHURA Biosciences, Inc./NV
- **CENTRAL INDEX KEY:** 0001498382
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 990360497
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 333-289532

**BUSINESS ADDRESS:**
- **STREET 1:** 10500 UNIVERSITY CENTER DR.
- **STREET 2:** SUITE 110
- **CITY:** TAMPA
- **STATE:** FL
- **ZIP:** 33612
- **BUSINESS PHONE:** 813-875-6600

**MAIL ADDRESS:**
- **STREET 1:** 10500 UNIVERSITY CENTER DR.
- **STREET 2:** SUITE 110
- **CITY:** TAMPA
- **STATE:** FL
- **ZIP:** 33612

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Kintara Therapeutics, Inc.
- **DATE OF NAME CHANGE:** 20200820

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** DelMar Pharmaceuticals, Inc.
- **DATE OF NAME CHANGE:** 20130123

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Berry Only Inc.
- **DATE OF NAME CHANGE:** 20100805
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001193125-25-179009

## Text-Extract

```

                                                             August 28, 2025

James Bianco
Chief Executive Officer
TuHURA Biosciences, Inc.
10500 University Center Drive, Suite 110
Tampa, FL 33612

       Re: TuHURA Biosciences, Inc.
           Registration Statement on Form S-1
           Response dated August 25, 2025
           File No. 333-289532
Dear James Bianco:

       We have reviewed your August 25, 2025 response to our comment letter and
have the
following comment.

        Please respond to this letter by amending your registration statement
and providing
the requested information. If you do not believe a comment applies to your
facts and
circumstances or do not believe an amendment is appropriate, please tell us why
in your
response.

       After reviewing any amendment to your registration statement and the
information
you provide in response to this letter, we may have additional comments.

Registration Statement on Form S-1
General

1.     We have evaluated your response and continue to note that the $3.7
million tranche is
       required to be purchased and funded on or before December 31, 2025.
Please expand
       the analysis in your response to address how this would comply with the
portion
       of Securities Act Sections Compliance and Disclosure Interpretations
Question 139.11
       which indicates that the closing of the private placement of the
unissued securities
       must occur within a "short time" after the effectiveness of the resale
registration
       statement. If the closing of this tranche will not occur within a short
time after the
       anticipated effectiveness of this registration statement, please revise
your registration
       statement as appropriate.
 August 28, 2025
Page 2

       Please contact Tyler Howes at 202-551-3370 or Tim Buchmiller at
202-551-3635
with any other questions.

                                                       Sincerely,

                                                       Division of Corporation
Finance
                                                       Office of Life Sciences
cc:   Curt P. Creely, Esq.

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._